|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
A comparative study between NHL associated either with BCL2 or BCL6 rearrangement showed that advanced disease and bone marrow involvement were more frequent in BCL2(+) NHL.
|
8703825 |
1996 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
One patient with follicular small cleaved cell NHL that evolved to a small noncleaved cell NHL had coexisting bcl-2 and c-myc rearrangement in the aspiration specimen of the high-grade NHL, suggesting sequential bcl-2 and c-myc activation during the tumor's progression.
|
2189291 |
1990 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
The NHL was considered a histological conversion from follicular lymphoma because lymphoma cells carried t(14;18) (q32;q21) and were strongly positive for BCL2 protein.
|
10700860 |
2000 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Conclusion Selective targeting of BCL-2 with venetoclax was well tolerated, and single-agent activity varied among NHL subtypes.
|
28095146 |
2017 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Ongoing clinical trials are exploring the role of Bcl-2 downregulation with oblimersen (Bcl-2 antisense) in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia and multiple myeloma.
|
15784299 |
2005 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Fourteen patients with FSCCL and 1 patient with DSCCL had a phenotype of follicular center cells (FCC) (CALLA+, SIgD-, Leu-1-, Leu-8- and negative ALPase), and 11 patients with FSCCL had bcl-2 gene rearrangements.
|
1643614 |
1992 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
DNA was extracted from archival CPs of B-cell NHL cases with previous fluorescence in situ hybridization (FISH) assays for MYC rearrangement and/or IGH/BCL-2 translocation.
|
25807917 |
2015 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
These modifications induced by rituximab were in large part responsible for the down-regulation of the anti-apoptotic gene products Bcl-2/Bcl-xL and chemosensitization of the drug-resistant B-NHL cell lines to various drug-induced apoptosis.
|
15939340 |
2005 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thirty-two patients diagnosed with non-Hodgkin lymphoma with concurrent MYC and BCL2 translocations from 2003 to 2013 were identified.
|
25656914 |
2015 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Preservation of functional and regulatory domains of expressed bcl-2 genes in non-Hodgkin's lymphoma.
|
8558921 |
1996 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
|
8574164 |
1995 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Twenty cases of Japanese non-Hodgkin's lymphoma with B cell markers were studied with respect to their immunoglobulin heavy (IgH) chain gene loci on chromosome 14 and BCL2 loci on chromosome 18.
|
1747446 |
1991 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
This study was planned with the aim to investigate the association between bcl-2 gene rearrangements and apoptotic changes during chemotherapy in patients with non-Hodgkin's lymphoma.
|
10074891 |
1999 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Fifty-one cases of intestinal non-Hodgkin's lymphoma (NHL) (10 small B-cell mucosa-associated lymphoid tissue [MALT] NHLs, 12 large B-cell MALT NHLs, 18 large B-cell NHLs, 2 small T-cell NHLs, 7 large T-cell NHLs, and 2 mantle cell NHLs) were studied for the immunohistochemical expression of MIB-1 and the TUNEL assay as well as the expression of bcl-2 and p53, both of which are regulatory gene products involved in apoptosis.
|
9655306 |
1998 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
High bcl-2 expression was more frequent in B-cell NHL (109 of 214, 51%) than in T-cell NHL (6 of 35, 17%) (P = .0004), and was heterogeneously distributed among the different histological subtypes.
|
8547651 |
1996 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
|
8528964 |
1995 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation.
|
3287162 |
1988 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, in another series of 11 patients and a NHL cell line, we demonstrated t(14;18) and t(11;14) in interphase and metaphase cells with a combination of BCL2 (or PRAD1) with IgH gene probes.
|
9209369 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
There appeared to be an impact of the BCL2 - 938AA genotype on advanced stage and - 248AG + AA genotypes on tumor size in NHL.
|
24024471 |
2014 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In our study, we investigated the prognostic significance of CD95, BCL2, and P53 expression in extranodal non-Hodgkin's lymphoma (NHL).
|
20352431 |
2010 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
We developed a (177)Lu-labeled bcl-2 antisense peptide nucleic acid (PNA)-peptide conjugate designed for dual modality NHL therapy, consisting of a radiopharmaceutical capable of simultaneously down-regulating apoptotic resistance and delivering cytotoxic internally emitted radiation.
|
24267052 |
2014 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The presence of a bcl-2 gene rearrangement in de novo DLCL suggests a possible follicle center cell origin and perhaps a distinct clinical behavior more akin to low-grade non-Hodgkin's lymphoma (NHL).
|
9207459 |
1997 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interestingly these fragile sites were located in the same chromosomal bands as the oncogenes, MOS, MYC, BCL-1 and BCL-2 as well as cancer breakpoints specifically associated with non-Hodgkin's lymphoma, suggesting the possibility that fragile sites may play a critical role in the pathogenesis of non-Hodgkin's lymphoma.
|
7954347 |
1994 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These figures are similar to those reported in the West, and therefore bcl-2 gene rearrangement does not help in explaining the epidemiological differences of NHL between Jordan and the West.
|
15770300 |
2005 |
|
Lymphoma, Non-Hodgkin
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Other studies have suggested an inverse relationship between p53 and bcl-2 protein expression in breast and colonic cancers and in a variety of subtypes of non-Hodgkin's lymphoma.
|
9349233 |
1997 |